The last day of November saw the Dow Jones Industrial Average
Companies with market caps under $150 million were screened out, as low valuations leave shares susceptible to bigger price swings. For instance, November's biggest plunge went to Alimera Sciences
Here are the five worst-performing health-care stocks in November. What you are about to see isn't pretty; parental discretion is advised.
% Change in Share Price
Human Genome Sciences
Source: S&P Capital IQ.
Investors are concerned that the increasing competition in hepatitis C treatments will leave Vertex's Incivek as a short-lived best-in-class treatment. Both Human Genome Sciences and Dendreon have struggled after disappointing launches for their respective drugs, Benlysta and Provenge. Seattle Genetics' tough month happened even after one analyst opened coverage on the company with a buy and a $20 price target, while another raised Seattle Genetics' Adcetris sales estimates. MAKO Surgical missed analyst earnings estimates by a penny and have trended down since.
But just because these five companies had a rough go of it in November, that doesn't mean the bad times will continue. Track tracking them using our free watchlist service, My Watchlist.
- Add Alimera Sciences to My Watchlist.
- Add Vertex Pharmaceuticals to My Watchlist.
- Add Seattle Genetics to My Watchlist.
- Add Human Genome Sciences to My Watchlist.
- Add Dendreon to My Watchlist.
- Add MAKO Surgical to My Watchlist.
If you think November's market moves were a big deal, wait until you read The Motley Fool's special free report, " The Next Trillion Dollar Revolution ." Don't miss out on your chance to profit from this massive opportunity before everyone else catches on.
David Williamson owns shares of Dendreon, but he holds no other position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Dendreon. Motley Fool newsletter services have recommended buying shares of MAKO Surgical and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.